Compare Adaptive Biotechnologies Corp (ADPT) vs YieldMax COIN Option Income Strategy ETF (CONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs YieldMax COIN Option Income Strategy ETF — how do they compare? Adaptive Biotechnologies Corp trades at $24.97 (market cap $4.04B), while YieldMax COIN Option Income Strategy ETF trades at $18.11. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, YieldMax COIN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | CONY | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $25.45 | $76.50 |
52-Week Low | $12.30 | $17.80 |
Enterprise Value | $4.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
CONY trades at $18.11, up 0.22% on the day, with a bearish technical signal driven by moving averages. The ETF shows no available valuation or profitability ratios, and recent news highlights weekly dividend distributions but also concerns over shareholder losses and declining value despite high yields. Technical indicators show RSI near oversold levels at 29.18, suggesting potential for a rebound, while resistance sits at $19.
The outlook remains cautious due to bearish technicals and negative media sentiment questioning sustainability. Risks include reliance on options income and market volatility. Analyst coverage is limited, with no consensus ratings or price targets available, indicating uncertainty for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About YieldMax COIN Option Income Strategy ETF
CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.
Read more on CONY →
